Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Craig-Hallum analyst William Bonello maintained a Buy rating on Navitas Semiconductor (NVTS – Research Report) today. The company’s shares ...

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on CareDx (CDNA – Research Report). The company’s shares ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Natera Inc. poached Guardant Health Inc. employees to steal trade secrets and jumpstart its “lagging position” in the early cancer test industry, according to a federal lawsuit. Former Guardant ...

Natera also broadened its patent infringement litigation against NeoGenomics (NASDAQ:NEO), involving the RaDaR assay. Despite a setback in a false advertising lawsuit against Guardant Health ...

This report describes and explains the liquid biopsy for cancer diagnostics market and covers 2019-2024, termed the historic ...